MX382054B - Composición farmacéutica que comprende derivado de quinolina o sal del mismo. - Google Patents

Composición farmacéutica que comprende derivado de quinolina o sal del mismo.

Info

Publication number
MX382054B
MX382054B MX2018008549A MX2018008549A MX382054B MX 382054 B MX382054 B MX 382054B MX 2018008549 A MX2018008549 A MX 2018008549A MX 2018008549 A MX2018008549 A MX 2018008549A MX 382054 B MX382054 B MX 382054B
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
salt
quinoline derivative
pharmaceutically acceptable
provides
Prior art date
Application number
MX2018008549A
Other languages
English (en)
Other versions
MX2018008549A (es
Inventor
Chenyang Wang
Xinhua Zhang
Yun Lu
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2018008549A publication Critical patent/MX2018008549A/es
Publication of MX382054B publication Critical patent/MX382054B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona una composición farmacéutica que comprende un derivado de quinolina o una sal del mismo. Específicamente, la invención proporciona una composición farmacéutica que comprende un (R, E)-N-(4-(3-cloro-4-(piridina-2-ilmetoxi)fenilamino) -3-ciano-7-etoxiquinolina-6-ilo)-3-(1-metilpirrolidina-2-il)-propeneamida o una sal farmacéuticamente aceptable de la misma, una polivinilpirrolidona reticulada y al menos un excipiente farmacéuticamente aceptable. La composición farmacéutica tiene una propiedad de disolución rápida.
MX2018008549A 2016-01-27 2017-01-23 Composición farmacéutica que comprende derivado de quinolina o sal del mismo. MX382054B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610056739 2016-01-27
PCT/CN2017/072155 WO2017129087A1 (zh) 2016-01-27 2017-01-23 一种含有喹啉衍生物或其盐的药物组合物

Publications (2)

Publication Number Publication Date
MX2018008549A MX2018008549A (es) 2018-09-19
MX382054B true MX382054B (es) 2025-03-13

Family

ID=59397432

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008549A MX382054B (es) 2016-01-27 2017-01-23 Composición farmacéutica que comprende derivado de quinolina o sal del mismo.

Country Status (13)

Country Link
US (1) US11065241B2 (es)
EP (1) EP3378478B1 (es)
JP (1) JP6864691B2 (es)
KR (1) KR102720987B1 (es)
CN (2) CN108354909B (es)
AU (1) AU2017212452B2 (es)
BR (1) BR112018014559A2 (es)
CA (1) CA3011525C (es)
HK (1) HK1243358B (es)
MX (1) MX382054B (es)
RU (1) RU2743014C2 (es)
TW (1) TWI726978B (es)
WO (1) WO2017129087A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3701948A4 (en) * 2017-10-24 2021-08-25 Jiangsu Hengrui Medicine Co., Ltd. PHARMACEUTICAL COMPOSITION WITH QUINOLINE DERIVATIVE

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101824029A (zh) * 2009-03-05 2010-09-08 厦门艾德生物医药科技有限公司 酪氨酸激酶不可逆抑制剂、其药物组合物及其用途
CN102020639A (zh) * 2009-09-14 2011-04-20 上海恒瑞医药有限公司 6-氨基喹唑啉或3-氰基喹啉类衍生物、其制备方法及其在医药上的应用
CN102675287A (zh) * 2011-03-11 2012-09-19 江苏恒瑞医药股份有限公司 (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用
CN103987700B (zh) * 2012-03-09 2016-08-31 江苏豪森药业集团有限公司 4-喹唑啉胺类衍生物及其用途
MA37711A1 (fr) * 2012-06-04 2017-05-31 Pharmacyclics Inc Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
CN103539783A (zh) * 2012-07-12 2014-01-29 江苏恒瑞医药股份有限公司 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法

Also Published As

Publication number Publication date
EP3378478A1 (en) 2018-09-26
TW201726135A (zh) 2017-08-01
KR102720987B1 (ko) 2024-10-24
TWI726978B (zh) 2021-05-11
KR20180103089A (ko) 2018-09-18
AU2017212452A1 (en) 2018-08-02
MX2018008549A (es) 2018-09-19
AU2017212452B2 (en) 2022-04-14
US11065241B2 (en) 2021-07-20
CA3011525C (en) 2023-12-05
EP3378478B1 (en) 2022-05-11
CN107405344B (zh) 2018-08-14
RU2018128411A (ru) 2020-02-27
EP3378478A4 (en) 2018-12-26
WO2017129087A1 (zh) 2017-08-03
CA3011525A1 (en) 2017-08-03
RU2743014C2 (ru) 2021-02-12
JP6864691B2 (ja) 2021-04-28
RU2018128411A3 (es) 2020-04-30
US20200138803A1 (en) 2020-05-07
HK1243358B (zh) 2019-08-16
CN108354909B (zh) 2021-05-14
CN107405344A (zh) 2017-11-28
BR112018014559A2 (pt) 2018-12-11
CN108354909A (zh) 2018-08-03
JP2019503366A (ja) 2019-02-07

Similar Documents

Publication Publication Date Title
SA520411524B1 (ar) مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
SA520411990B1 (ar) مركبات مفيدة لتثبيط إنزيم كيناز 7 المعتمد على السيكلين
MX2023000085A (es) Compuestos antiproliferativos y metodos para utilizarlos.
SA519401336B1 (ar) تركيبة صيدلية
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
PH12018502109A1 (en) Medicine obtained by combining fxr agonist and arb
EP3181559A4 (en) 2-(2,4,5-substituted aniline) pyrimidine derivative, pharmaceutical composition and use thereof
HUE063879T2 (hu) 4-(l,3,4-oxadiazol-2-il)piridin-2(lH)-on származékok mint hiszton-deacetiláz 6 (HDAC6) inhibitorok például a fertõzések kezelésében
MX2017006447A (es) Agentes antifungicos.
ZA202004548B (en) Nitrogenated heterocyclic amide compound, and use thereof for medical purposes
TN2016000489A1 (en) Carboxamide derivatives.
MX384034B (es) Agente terapeutico para cancer de mama.
EP4339192A3 (en) Compounds and compositions for the treatment of cancer
SG11202101451QA (en) Novel heterocyclic amine derivative and pharmaceutical composition comprising same
GB2590189B (en) Lycorine derivative, and pharmaceutical composition and use thereof
TN2016000491A1 (en) Carboxamide derivatives.
PH12017500436A1 (en) Novel pharmaceutical composition for prevention and/or treatment of urinary incontinence
MX2019008338A (es) Composicion farmaceutica que contiene sulglicotido o una sal farmaceuticamente aceptable del mismo para la prevencion o tratamiento del ojo seco.
BR112018014559A2 (pt) composição farmacêutica compreendendo um derivado de quinolina ou sal da mesma
MX380123B (es) Metodo para preparar una composicion farmaceutica que comprende un derivado de quinolina o una sal del mismo.
AR111255A1 (es) Derivados de 4-piperidin-n-(pirimidin-4-il)croman-7-sulfonamidas inhibidores de canales de sodio
EA201991007A1 (ru) Твердые фармацевтические композиции на основе гидрохлорида луразидона для перорального применения
EA201990506A1 (ru) Фармацевтическая композиция
WO2019209208A3 (en) Controlled-release pharmaceutical compositions of ivabradine